An observational study in Osteoporosis and Chronic Kidney Disease Mineral and Bone Disorder, sponsored by Universidade do Porto. Not yet recruiting at 1 site in Portugal. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Universidade do Porto · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Osteoporosis, a silent and multifactorial systemic skeletal disorder, severely compromises bone strength and significantly increases the risk of fragility fractures. Despite its high prevalence (affecting \~10% of Portuguese over 50), it remains critically underdiagnosed and undertreated, with over 80% of fragility fractures occurring in untreated individuals.
Chronic Kidney Disease (CKD) profoundly exacerbates bone fragility, giving rise to CKD-associated osteoporosis, a complex skeletal disorder often integrated within CKD-Mineral and Bone Disorder. This systemic dysregulation of mineral metabolism not only impairs bone quality but also actively promotes vascular calcification and significantly elevates cardiovascular disease risk, underscoring a critical kidney-bone-vascular nexus. Despite these well-established links, CKD-associated osteoporosis is similarly underdiagnosed and undertreated, partly due to diagnostic challenges related to Bone Mineral Density interpretation and therapeutic hesitancy in this complex patient population.
This multi-phase observational study is designed to address the significant public health challenges posed by osteoporosis and by osteoporosis associated with CKD in Portugal, particularly among individuals aged 40 years to 90 years. The study aims to enhance understanding of disease prevalence, identify diagnostic and treatment gaps, and evaluate management trajectories, while emphasizing the intricate interrelationships among bone health, renal function, and cardiovascular risk.
1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.
This study's planned enrollment of 622 is above the median of 160 across 456 observational studies indexed under Osteoporosis.
Browse Osteoporosis studies →Universidade do Porto is the lead sponsor of 174 studies on the registry; 53 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population comprises adults aged 40 to 90 years registered at the Primary Healthcare Units of the ULS de Barcelos/Esposende
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A random sample stratified by age and gender distribution from the pre-screening USF list will undergo osteoporotic fracture risk assessment via a validated, Portugal-adapted FRAX® algorithm conducted via structured telephone interviews.
All participants with a moderate/high fracture risk for osteoporosis will undergo Bone Mineral Density assessment by DXA, as well as a subsample of low fracture risk patients.
Prevalence of Osteoporosis
Weighted proportion of the population screened (individuals aged between 40 and 90 years) diagnosed with osteoporosis by Dual-Energy X-ray Absorptiometry (T-score ≤ -2.5).
Time frame: Baseline
Fracture Risk
Fracture risk assessment with the Portuguese-adapted FRAX®. Patients will be categorized in low fracture risk, moderate fracture risk and high fracture risk.
Time frame: Baseline
Prevalence of CKD-associated Osteoporosis
Proportion of individuals with CKD meeting osteoporosis diagnostic criteria
Time frame: Baseline and 3 months
Creatinine
Serum levels of Creatinine (mg/dL)
Time frame: Baseline, 3 months and 12 months
eGFR
Estimated glomerular filtration rate (eGFR) calculated by the CKD-EPI equation.
Time frame: Baseline, 3 months and 12 months
Calcium
Serum levels of Calcium (mg/dL)
Time frame: Baseline and 12 months
Phosphate
Serum levels of phosphate (mg/dL)
Time frame: Baseline and 12 months
Alkaline phosphatase
Serum levels of Alkaline phosphatase (U/L)
Time frame: Baseline and 12 months
25-Hydroxyvitamin D
Serum levels of 25-Hydroxyvitamin D (ng/mL)
Time frame: Baseline and 12 months
Parathyroid Hormone
Serum levels of Parathyroid Hormone (pg/mL)
Time frame: Baseline and 12 months
P1NP
Serum levels of N-terminal propeptide of type 1 procollagen (P1NP) (ng/mL)
Time frame: Baseline and 12 months
CTX
Serum levels of C-terminal cross-linked telopeptide of type 1 collagen (CTX) (pf/mL)
Time frame: Baseline and 12 months
Health-related quality of life score (EQ-5D-5L)
Quality of life evaluated using the EQ-5D-5L questionnaire, assessing disease control trajectories and comparing individuals with osteoporosis, with and without CKD.
Time frame: Baseline and 12 months
Medication adherence score (ERAM-7)
Adherence to pharmacological treatment evaluated using the scale "Escala de AutoReporte de Adesão à Medicação" (ERAM-7).
Time frame: Baseline and 12 months
Sclerostin
Serum levels of Sclerostin (pmol/L)
Time frame: Baseline and 12 months
RANKL
Serum levels of RANKL (Receptor Activator of NF-KB Ligand) (pg/mL)
Time frame: Baseline and 12 months
Osteoprotegerin
Serum levels of Osteoprotegerin (pg/mL)
Time frame: Baseline and 12 months
FGF23
Serum levels of FGF23 (Fibroblast Growth Factor-23) (RU/mL)
Time frame: Baseline and 12 months
Start is estimated for Oct 2026; primary completion for Sep 2027, 11 months later.
Of 115 non-industry observational studies under Osteoporosis, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 113. This study's planned 11 months is below that.
Counting every sponsor, half of 126 studies reached it within 51 months; a quarter within 24 and three quarters within 97.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.